KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Goodwill (2016 - 2026)

Eli Lilly filings provide 18 years of Goodwill readings, the most recent being $6.1 billion for Q1 2026.

  • On a quarterly basis, Goodwill rose 6.23% to $6.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.1 billion, a 6.23% increase, with the full-year FY2025 number at $5.9 billion, up 2.22% from a year prior.
  • Goodwill hit $6.1 billion in Q1 2026 for Eli Lilly, up from $5.9 billion in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $6.1 billion in Q1 2026 to a low of $3.9 billion in Q3 2022.
  • Median Goodwill over the past 5 years was $4.9 billion (2023), compared with a mean of $5.0 billion.
  • Biggest five-year swings in Goodwill: surged 41.42% in 2024 and later rose 0.04% in 2025.
  • Eli Lilly's Goodwill stood at $4.1 billion in 2022, then rose by 21.28% to $4.9 billion in 2023, then grew by 16.81% to $5.8 billion in 2024, then rose by 2.22% to $5.9 billion in 2025, then increased by 3.93% to $6.1 billion in 2026.
  • The last three reported values for Goodwill were $6.1 billion (Q1 2026), $5.9 billion (Q4 2025), and $5.9 billion (Q3 2025) per Business Quant data.